Tyra Biosciences, Inc.
TYRA Nasdaq
SEC CIK 1863127
Follow Tyra Biosciences
Weekly email: filings, results
Net income
−$51.1M
−71.2% vs same quarter last year
EPS, diluted
−$0.74
−48% vs same quarter last year
Operating cash flow
−$32.2M
−43.9% vs same quarter last year
Operating income
−$54.9M
−66.6% vs same quarter last year
Source: SEC XBRL filings · latest filing
Show the numbers
| Year | Net income |
|---|---|
| FY25 | −$119.9M |
| FY24 | −$86.5M |
| FY23 | −$69.1M |
| FY22 | −$55.3M |
| FY21 | −$26.3M |
| FY20 | −$9.3M |
| FY19 | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −$95.3M |
| FY24 | −$70.4M |
| FY23 | −$50.9M |
| FY22 | −$50.8M |
| FY21 | −$24.4M |
| FY20 | −$8.1M |
| FY19 | - |